TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19430098
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of thumb-connection domain between treatment-experienced and treatment-naive patients
Study: 19430098
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of RNase H domain between treatment-experienced and treatment-naive patients
Study: 11867826
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (1000 microg daily) for 3 weeks
Study: 7849886
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (aminophylline)
Study: 2083923
Drug: S-adenosylmethionine (SAMe)
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine (SAMe) 800 mg/day i.v.
Study: 7211263
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg metoprolol tablet
Study: 7211263
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg metoprolol tablet
Study: 7211263
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg metoprolol tablet
Study: 7211263
Drug: 1% metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% metoprolol eye drops administered twice daily for 6 weeks
Study: 19477358
Drug: Intravenous ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ANP (0.025 microg/kg/min for 3 days)
Study: 17320191
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for depression
Study: 14996517
Drug: High-dose clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clarithromycin 500 mg twice daily for 10 days
Study: 15014819
Drug: Fentanyl 4
Normalized name: fentanyl 400 MCG Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 4 microg/kg and midazolam 0.04 mg/kg
Study: 6228473
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine in combination with Hepatitis B immunoglobulin
Study: 29912819
Drug: Control (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (continued medical therapy)
Study: 16330766
Drug: Gabapentin (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1,800 mg per os, single administration)
Study: 12059873
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone pulse therapy (group A)
Study: 12059873
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (group B)
Study: 8758124
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate 200 micrograms twice daily for six months
Study: 1736604
Drug: Dipyridamole 75
Normalized name: dipyridamole 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 75 mg every 8 hours for 2 weeks
Study: 328328
Drug: Penbutolol 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 25 mg and 50 mg (in 10 patients); 25 mg, 50 mg, and 100 mg (in 2 patients)
Study: 30762404
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation counseling adjunct (LP1)
Study: 30762404
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation counseling adjunct (LP2)
Study: 30762404
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation counseling adjunct (LP3)
Study: 29083433
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (150kcal, 20g whey protein, 800 IU vitamin D)
Study: 23001082
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (1 g ampicillin-sulbactam intravenously at anesthesia)
Study: 22108482
Drug: mf Odontovis
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mf Odontovis Calcium® (calcium salts, Vitamin D, and physiological modulators with antioxidant activity)
Study: 22108482
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (best treatment without mf Odontovis Calcium®)
Study: 16167938
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid restriction and BP target of 95-105 mmHg
Study: 14572325
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension administered with an Adaptive Aerosol Delivery (AAD) system
Study: 2694097
Drug: Pentoxifylline (Trental)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (Trental) intravenous treatment
Study: 2694097
Drug: Pentoxifylline (Trental)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (Trental) oral treatment
Study: 2694097
Drug: Placebo (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control) intravenous treatment
Study: 18317392
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg prednisone for 5 days, followed by gradually reduced doses for an additional 15 days, and vestibular sedatives for symptomatic relief during the first 5 days.
Study: 18317392
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and similar vestibular sedatives.
Study: 8649929
Drug: Agarose gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agarose gel electrophoresis (ethidium bromide staining)
Study: 8649929
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of specific anti-HCMV antibodies
Study: 2121016
Drug: Recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) followed by heparin
Study: 526908
Drug: Rubidazone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubidazone (150 mg/m2 iv over 1 hour)
Study: 526908
Drug: Adriamycin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (60 mg/m2 iv over 5 minutes)
Study: 526908
Drug: Adriamycin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (60 mg/m2 iv over 5 minutes) after rubidazone failure
Study: 27178566
Drug: Dual-coated probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-coated probiotics (Duolac Care), 2 capsules per day, 5 billion bacteria per capsule for 4 weeks
Study: 25607519
Drug: Supplement (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement (vitamin C:1000mg/d; vitamin E: 400 IU/d)
Study: 19229549
Drug: Carbetocin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100 microg IV injection)
Study: 19229549
Drug: Oxytocin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (10 IU IV infusion over 2 hours)
Study: 12871368
Drug: Ximelagatran 20
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 20 mg
Study: 12871368
Drug: Ximelagatran 40
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 40 mg
Study: 12871368
Drug: Ximelagatran 80
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 80 mg
Study: 8932891
Drug: Glycine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (0.8 g/kg body weight/day)
Study: 28419778
Drug: Raltegravir 600
Normalized name: raltegravir 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 600 mg formulation
Study: 28419778
Drug: Raltegravir 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 3 × 400 mg and 2 × 600 mg dosage forms
Study: 28419778
Drug: Raltegravir 2
Normalized name: raltegravir 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 2 × 600 mg formulation
Study: 28419778
Drug: Raltegravir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 1200 mg
Study: 28419778
Drug: Raltegravir multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir multiple doses
Study: 24119859
Drug: Humor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humor therapy intervention provided by ElderClowns for 2-hour sessions, 9-12 times over 12 weeks.
Study: 24119859
Drug: Humor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humor therapy intervention
Study: 22249997
Drug: Ecosystem Focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecosystem Focused Therapy (EFT)
Study: 18062519
Drug: Propofol mixed
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol mixed with 2cc of a solution containing phenylephrine 100 microg/cc (total 100 microg)
Study: 18062519
Drug: Propofol mixed
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol mixed with 2cc of a solution containing phenylephrine 50 microg/cc (total 50 microg)
Study: 12068252
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all tests
Study: 1742901
Drug: Clindamycin, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin, 150 mg 4 times daily for 10 days
Study: 6743780
Drug: Zopiclone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (7.5 mg) + Trimipramine (50 mg)
Study: 28870242
Drug: Intraoperative wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative wound irrigation with 0.04% polyhexanide (PHX) solution
Study: 26152221
Drug: Insulin intensive
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin intensive therapy
Study: 26152221
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with continuation of pre‐CR antidiabetic treatment
Study: 15567112
Drug: Treatment outcomes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment outcomes (adherence and weight loss)
Study: 11068858
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x weekly narrow-band UVB treatment
Study: 11068858
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x weekly narrow-band UVB treatment
Study: 2439786
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 mg and 20 mg)
Study: 2738457
Drug: Sensory Integrative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory Integrative Therapy (SIT) program
Study: 31740348
Drug: Doravirine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine (100 mg per day)
Study: 31740348
Drug: Ritonavir-boosted darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted darunavir (100 mg ritonavir and 800 mg darunavir per day)
Study: 26165919
Drug: Cognitive-behavioural suicide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural suicide prevention (CBSP) therapy
Study: 23943299
Drug: Deferred hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred hormonal therapy (D(HT))
Study: 23943299
Drug: Chemotherapy (CHT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CHT)
Study: 21930653
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (treated only with antiarrhythmic drugs for 6 weeks)
Study: 18985146
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (desipramine or fluoxetine) for 8 weeks
Study: 16870913
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (20 ppm, decreasing concentrations for a minimum of 24 days)
Study: 11377900
Drug: Fixed dorzolamide-timolol
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dorzolamide-timolol combination
Study: 9243107
Drug: Oral 17
Normalized name: polyoxypropylene (17)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17 beta-estradiol for 6 weeks
Study: 3448453
Drug: Microencapsulated formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microencapsulated formulation (C)
Study: 3448453
Drug: Highly buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly buffered formulation (A)
Study: 3448453
Drug: Cytoprotective formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoprotective formulation (B)
Study: 3448453
Drug: Plain tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain tablet formulation (D)
Study: 27565270
Drug: ICS +
Normalized name: Culturelle Probiotics + Multivitamin Gummies (Mixed Berry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS + LABA treatment
Study: 27565270
Drug: ICS +
Normalized name: Culturelle Probiotics + Multivitamin Gummies (Mixed Berry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS + LTRA treatment
Study: 25335330
Drug: Yishen Jiejing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishen Jiejing Decoction (YJD), 50 mL, twice a day for one month
Study: 23050578
Drug: Nurse-led empowerment-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led empowerment-based intervention (eight weekly sessions including lifestyle modification education, empowerment group discussions, and exercise training)
Study: 11094863
Drug: High-protein, very
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein, very low-calorie diet (VLCD; protein intake 1.5 to 2.0 g/kg of ideal body weight per day; 800 kcal/d) with weekly 2-hour clinic sessions including nutrition instruction, moderate-intensity exercise, and behavior-modification techniques.
Study: 3086721
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of penicillin V potassium twice daily
Study: 31441895
Drug: Juglandis semen
Normalized name: Hippocastani semen
DrugBank: Horse chestnut (DB13195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juglandis semen complex extract (JCE) 1000 mg
Study: 31441895
Drug: Juglandis semen
Normalized name: Hippocastani semen
DrugBank: Horse chestnut (DB13195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juglandis semen complex extract (JCE) 2000 mg
Study: 25684164
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet treatment (126 participants)
Study: 25684164
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment (124 participants)
Study: 25684164
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet treatment (101 participants, per-protocol analysis)
Study: 25684164
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment (96 participants, per-protocol analysis)
Study: 22387567
Drug: Cinacalcet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet plus low-dose vitamin D
Study: 10193284
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of analgesia
Study: 16470086
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral magnesium oxide daily
Study: 15009817
Drug: Low-dose clonidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose clonidine (25 micro g)
Study: 15009817
Drug: Medium-dose clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose clonidine (150 micro g)
Study: 10968501
Drug: Salbutamol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (100 microg x puff(‐1)) via metered-dose inhaler (MDI) under pressure control (decelerating flow pattern)
Study: 9247980
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 35% CO2 gas mixture
Study: 9247980
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of compressed air (control)
Study: 7878168
Drug: Diazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.1 mg/kg body weight i.v.)
Study: 2094946
Drug: Controlled-release salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release salbutamol (Group B)
Study: 367406
Drug: Phenytoin treatment
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin treatment (aimed at maintaining plasma phenytoin levels between 40 and 80 mumol/litre)
Study: 367406
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no phenytoin treatment)
Study: 22564709
Drug: Lixisenatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (20 µg once daily)
Study: 15588905
Drug: Transdermal iontophoretic
Normalized name: SYSTEM, TRANSDERMAL IONTOPHORETIC PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal iontophoretic delivery of R‐apomorphine with surfactant formulation pretreatment
Study: 15588905
Drug: Transdermal iontophoretic
Normalized name: SYSTEM, TRANSDERMAL IONTOPHORETIC PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal iontophoretic delivery of R‐apomorphine without surfactant formulation (control)
Study: 12122510
Drug: Intravenous liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous liposomal amphotericin B + oral itraconazole
Study: 8537671
Drug: 7‐valent pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐valent pneumococcal conjugate vaccine (7‐OMPC) followed by one dose of 23‐valent polysaccharide pneumococcal vaccine (23‐PS)
Study: 8537671
Drug: 23‐valent polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23‐valent polysaccharide pneumococcal vaccine (23‐PS) only
Study: 1864539
Drug: Oral eudragit
Normalized name: EUDRAGIT RS 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral eudragit S coated 5 amino salicylic acid (n = 12)
Study: 1864539
Drug: Rectal prednisolone
Normalized name: prednisolone Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal prednisolone enemas (n = 15)
Study: 6357175
Drug: Cotrimoxazole injection
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole injection and placebo suppository
Study: 6357175
Drug: Metronidazole suppository
Normalized name: metronidazole Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole suppository and cotrimoxazole injection
Study: 6357175
Drug: Metronidazole suppository
Normalized name: metronidazole Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole suppository and placebo injection
Study: 6357175
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository and placebo injection
Study: 23222095
Drug: Buprenorphine taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine taper (7 vs 28 days)
Study: 21272849
Drug: Prostaglandin E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E(2) controlled-release vaginal insert
Study: 19304880
Drug: Granisetron transdermal
Normalized name: Granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron transdermal patch (52 cm²)
Study: 19304880
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron (2 mg)
Study: 16730534
Drug: Intratympanic steroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic steroid treatment (0.5 mL of methylprednisolone acetate, 80 mg/2 mL, administered 4 times over 15 days)
Study: 16730534
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intratympanic treatment)
Study: 12577354
Drug: Composite indigo
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite indigo capsule (control)
Study: 29869538
Drug: Topical Coqun
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Coqun (100 mg CQ10, 500 mg Vitamin E TPGS) twice daily for 1 month preoperatively
Study: 29869538
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (pseudo-exfoliative glaucoma group)
Study: 29971527
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dapagliflozin (n=21)
Study: 29971527
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g OM‐3CA (n=20)
Study: 29971527
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dapagliflozin and OM‐3CA (n=22)
Study: 22433020
Drug: Clarithromycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (15 mg/kg for 3 weeks)
Study: 22433020
Drug: Control (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (regular GINA-guided exacerbation treatment)
Study: 18506618
Drug: Assertive Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive Community Treatment Only (ACTO)
Study: 18506618
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by time interactions